PhD thesis (University of London, 2002):
“Anti-epileptic drugs: economic considerations in clinical practice”
The economic impact of anti-epileptic drugs was investigated using modelling techniques and also methods that incorporated patient preferences. Research was based on a large number of patient interviews performed within a clinical setting. Socio-economic factors were considered. Cost-effectiveness and cost-benefit analyses were performed. Overall, my research demonstrated that economic evaluation is most meaningful in clinical practice when it incorporates patient opinion.
Heaney D, Baxendale S “Epilepsy & gambling: Risk factors for problem gambling behaviors in people with epilepsy” Epilepsy Behaviour. 2021 Sep;122:108082
Neligan A, Heaney D, Rajakulendran S. Is a separate clinical pathway for first seizures justified? Appraisal of the first seizure pathway at a tertiary neuroscience centre Seizure. 2021 Jan;84:108-111.
Baxendale S, Heaney D. Memory complaints in the epilepsy clinic Pract Neurol. 2020 Sep 19: practneurol-2020-002523
Baxendale S, Heaney D, Rugg-Gunn F, Friedland D Neuropsychological outcomes following traumatic brain injury Pract Neurol. 2019 Dec;19(6):476-482
Ridsdale L, et al Characteristics associated with quality of life among people with drug-resistant epilepsy.J Neurol. 2017 Jun;264(6):1174-1184
Amini,A… Heaney D Multiple sequential anti-body associated syndromes with a recurrent mutated neuroblastoma. Neurology 2016 87(6):
Baxendale S… Heaney D. The role of obesity in cognitive dysfunction in people with epilepsy. Epilepsy Behav. 2015 Apr;45:187-90
Zaccara G… Heaney DC. Network meta-analysis and the comparison of efficacy and tolerability of anti-epileptic drugs for treatment of refractory focal epilepsy. BJCP 2013 76(5):827-8
Baxendale S… Heaney D. Bright light therapy for symptoms of anxiety and depression in focal epilepsy: randomised controlled trial. Br J Psych. 2013 202(5):352-6
Baxendale S… Heaney D. Bright light therapy as an add on treatment for medically intractable epilepsy. Epi Behav. 2012 24(3):359-64
Baxendale S, Heaney D. Socioeconomic status, cognition, and hippocampal sclerosis. Epilepsy Behav. 2011 Jan;20(1):64-7.
Baxendale S, Heaney D, Thompson PJ, Duncan JS. Cognitive consequences of childhood-onset temporal lobe epilepsy across the adult lifespan. Neurology. 2010 Aug 24;75(8):705-11.
Adderley K. Low social class adversely affects outcome of epilepsy surgery. City of London MSc, awarded distinction. Supervised by Heaney D
Yuen AW, Singh R, Bell GS, Bhattacharjee A, Neligan A, Heaney DC, Duncan JS, Sander JW. The long-term retention of pregabalin in a large cohort of patients with epilepsy at a tertiary referral centre. Epilepsy Res. 2009 Dec;87(2-3):120-3.
Bensimon G, Ludolph A, Agid Y, Vidailhet M, Payan C, Leigh PN; NNIPPS Study Group. Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. Brain. 2009 Jan;132(Pt 1):156-71.
Yogarajah M, Powell HW, Heaney D, Smith SJ, Duncan JS, Sisodiya SM. Long term monitoring in refractory epilepsy: the Gowers Unit experience. J Neurol Neurosurg Psychiatry. 2009 Mar;80(3):305-10.
Webb TE, Pal S, Siddique D, Heaney DC, Linehan JM, Wadsworth JD, Joiner S, Beck J, Wroe SJ, Stevenson V, Brandner S, Mead S, Collinge J. First report of Creutzfeldt-Jakob disease occurring in 2 siblings unexplained by PRNP mutation. J Neuropathol Exp Neurol. 2008 Sep;67(9):838-41.
Heaney DC, Bell GS, Sander JW. The socioeconomic, cultural, and emotional implications of starting or withholding treatment in a patient with a first seizure. Epilepsia. 2008; 49 Suppl 1:35-9 Heaney DC, Sander JW. “The unknown cost of epilepsy misdiagnosis in England and Wales”. Seizure. 2007 Jun;16(4):377
Heaney D, Sander JW. “Antiepileptic drugs: generic versus branded treatments”. Lancet Neurology 2007 May;6(5):465-8.
Chataway J, Porter B, Riazi A, Heaney D, Watt H, Hobart J, Thompson A. “Home versus outpatient administration of intravenous steroids for multiple-sclerosis relapses: a randomised controlled trial”. Lancet Neurology. 2006 Jul;5(7):565-71
Heaney D, Sander JWAS. Cost-effectiveness of Carbamazepine. Expert Review of Pharmaco-economics and Outcomes Research 2006 Vol. 6 No. 1 Pages 13-18
Farrell R??, Heaney D, Giovannoni?? G. Emerging disease modifying therapies for multiple sclerosis. Expert Opinion Emerging Drugs 2005, Vol. 10, No. 4, Pages 797-816
Heaney D, Swash M, Geddes M et al. Sarcoid polyneuropathy responsive to intravenous immunoglobulin. Muscle Nerve 2004; 29(3): 447-50
Heaney D et al. Socioeconomic variation in incidence of epilepsy: prospective community based study in south east England. BMJ 2002; 325:1013-6.
Begley C et al. ILAE Commission on the Burden of Epilepsy, Subcommission on the Economic Burden of Epilepsy: Final report 1998-2001. Epilepsia 2002;43(6):668-73
MacDonald BK, Mummery CJ, Heaney D. Health needs of asylum seekers and refugees. Head injury needs to be taken into consideration in survivors of torture. BMJ 2001; 323:230
Book Chapters and Reports:
Heaney D, Williams D, O’Brien P – Neurological complications in pregnancy. In: De Swient’s Medical Disorders in Pregnancy. Ed Powrie, R et al. 2010
Heaney D, Shorvon SD. Epilepsy – Epidemiology, definitions and diagnostic procedures. In: Women with epilepsy – a handbook of health and treatment issues. Ed Morrell,M. 1st edition 2003
Heaney D, Sander JW. Cost benefit analysis in epilepsy. In: Epilepsy in Latin America. Ed. Devilat M, Campos M, Marinis A. 1st edition. Catholic University of Chile Press 2000
Shorvon SD, Thompson P, Heaney D. Epilepsy. In: Neurological Rehabilitation. Ed. Greenwood RJ, Barnes M, McMillan T, Ward D. 2nd edition. Churchill Livingstone Press 2000
Heaney D, Shorvon SD. Topiramate. In: A Handbook of Clinical Pharmacology. Ed. Eadie MJ. 2nd Edition.